Cargando…
ACE2, a promising therapeutic target for pulmonary hypertension
Pulmonary arterial hypertension (PAH) is a chronic lung disease with poor diagnosis and limited therapeutic options. The currently available therapies are ineffective in improving the quality of life and reducing mortality rates. There exists a clear unmet medical need to treat this disease, which n...
Autores principales: | Shenoy, Vinayak, Qi, Yanfei, Katovich, Michael J, Raizada, Mohan K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd. Published by Elsevier Ltd.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075309/ https://www.ncbi.nlm.nih.gov/pubmed/21215698 http://dx.doi.org/10.1016/j.coph.2010.12.002 |
Ejemplares similares
-
Neuroinflammation in Pulmonary Hypertension: Concept, Facts, and Relevance
por: Hilzendeger, Aline M., et al.
Publicado: (2014) -
Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Axis: Emerging Pharmacological Target for Pulmonary Diseases
por: Shenoy, Vinayak, et al.
Publicado: (2015) -
Current and Future Novel Targets of Gene Therapy for Hypertension
por: Katovich, Michael J., et al.
Publicado: (2005) -
The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury
por: Rathinasabapathy, Anandharajan, et al.
Publicado: (2018) -
ACE2 overexpression in corticotropin-releasing-hormone cells offers protection against pulmonary hypertension
por: Oliveira, Aline C., et al.
Publicado: (2023)